Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
February 18, 2022 16:00 ET
|
Kala Pharmaceuticals, Inc.
ARLINGTON, Mass., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement...
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
December 17, 2021 16:01 ET
|
Kala Pharmaceuticals, Inc.
WATERTOWN, Mass., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement...
Kala Pharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 18, 2021 16:01 ET
|
Kala Pharmaceuticals, Inc.
WATERTOWN, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement...
Kala Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 15, 2021 08:47 ET
|
Kala Pharmaceuticals, Inc.
-- Achieved $3.1 Million in Net Revenue in 3Q 2021 ---- EYSUVIS® Prescriptions Increased by 19% Compared to 2Q 2021-- Expanding Clinical-Stage Pipeline Through Acquisition of Combangio ---- Conference...
Kala Pharmaceuticals Acquires Combangio, Expanding its Pipeline with a Clinical-Stage Novel Biologic for the Treatment of Persistent Corneal Epithelial Defect (PCED) and other Rare Ocular Surface Diseases
November 15, 2021 08:45 ET
|
Kala Pharmaceuticals, Inc.
-- KPI-012 is a novel secretome with a multifactorial mechanism of action for development in PCED and other orphan ocular surface diseases driven by impaired corneal healing ---- KPI-012 demonstrated...
Kala Pharmaceuticals Announces Time Change for Third Quarter 2021 Financial Results Conference Call
November 15, 2021 07:00 ET
|
Kala Pharmaceuticals, Inc.
WATERTOWN, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization...
Kala Pharmaceuticals to Participate in Upcoming Investor Conferences in November 2021
November 11, 2021 08:00 ET
|
Kala Pharmaceuticals, Inc.
WATERTOWN, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization...
Kala Pharmaceuticals to Report Third Quarter 2021 Financial Results and Host Conference Call
November 08, 2021 16:01 ET
|
Kala Pharmaceuticals, Inc.
WATERTOWN, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization...
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
October 22, 2021 16:01 ET
|
Kala Pharmaceuticals, Inc.
WATERTOWN, Mass., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement...
Kala Pharmaceuticals Announces Appointment of C. Daniel Myers to Board of Directors
October 18, 2021 08:00 ET
|
Kala Pharmaceuticals, Inc.
WATERTOWN, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization...